ACAD - ACADIA Pharmaceuticals Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
ACAD price evolution
ACAD
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $182.9 | $210.51 | $194.43 | |
| Short term investments | $323.81 | $265.77 | $250.21 | |
| Net receivables | $110.36 | $110.39 | $100.08 | $102.35 |
| Inventory | $61.04 | $86.07 | $66.64 | $40.45 |
| Total current assets | $788.28 | $728.92 | $675.3 | $616.13 |
| Long term investments | ||||
| Property, plant & equipment | $48.24 | $56.53 | $58.65 | $56.47 |
| Goodwill & intangible assets | $107.86 | $110.2 | $65.49 | |
| Total noncurrent assets | $185.18 | $179.81 | $132.83 | |
| Total investments | $323.81 | $265.77 | $250.21 | |
| Total assets | $976.87 | $914.1 | $855.1 | $748.96 |
| Current liabilities | ||||
| Accounts payable | $19.08 | $19.88 | $19.33 | $17.54 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $343.94 | $337.85 | $330.6 | $254.25 |
| Long term debt | $47.19 | $49.19 | $47.8 | |
| Total noncurrent liabilities | $59.55 | $60.46 | $62.95 | |
| Total debt | $47.19 | $49.19 | $47.8 | |
| Total liabilities | $399.69 | $397.4 | $391.06 | $317.2 |
| Shareholders' equity | ||||
| Retained earnings | -$2348.13 | -$2380.89 | -$2414.28 | -$2430.84 |
| Other shareholder equity | $0.86 | -$0.34 | -$0.23 | $0.02 |
| Total shareholder equity | $516.7 | $464.04 | $431.75 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $194.43 | $120.62 | $153.21 | $331.8 |
| Short term investments | $250.21 | $301.98 | $373.27 | $305.93 |
| Net receivables | $102.35 | $63.08 | $65.34 | $50.28 |
| Inventory | $40.45 | $6.64 | $14.1 | $9.68 |
| Total current assets | $616.13 | $507.94 | $617.82 | $717.62 |
| Long term investments | ||||
| Property, plant & equipment | $56.47 | $61.59 | $66.31 | $56.44 |
| Goodwill & intangible assets | $65.49 | $1.11 | ||
| Total noncurrent assets | $132.83 | $79.88 | $82.3 | $65 |
| Total investments | $250.21 | $301.98 | $373.27 | $305.93 |
| Total assets | $748.96 | $587.81 | $700.12 | $782.62 |
| Current liabilities | ||||
| Accounts payable | $17.54 | $12.75 | $6.88 | $8.49 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $254.25 | $125.63 | $96.07 | $105.97 |
| Long term debt | $47.8 | $52.7 | $56.13 | $44.46 |
| Total noncurrent liabilities | $62.95 | $61.77 | $63.16 | $49.64 |
| Total debt | $47.8 | $52.7 | $56.13 | $44.46 |
| Total liabilities | $317.2 | $187.4 | $159.23 | $155.61 |
| Shareholders' equity | ||||
| Retained earnings | -$2430.84 | -$2369.55 | -$2153.58 | -$1985.71 |
| Other shareholder equity | $0.02 | -$0.97 | -$0.19 | $0.04 |
| Total shareholder equity | $431.75 | $400.41 | $540.89 | $627.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $250.4 | $241.96 | $205.83 | $231.04 |
| Cost of revenue | $18.23 | $22.95 | $17.89 | |
| Gross Profit | $231.54 | $223.73 | $182.88 | $213.15 |
| Operating activities | ||||
| Research & development | $76.23 | $59.68 | $66.74 | |
| Selling, general & administrative | $117.06 | $107.99 | $111.47 | |
| Total operating expenses | $199.9 | $193.3 | $167.67 | $178.21 |
| Operating income | $30.44 | $15.21 | $34.94 | |
| Income from continuing operations | ||||
| EBIT | $37.18 | $21 | $39.7 | |
| Income tax expense | $6.04 | $3.79 | $4.45 | -$6.09 |
| Interest expense | $6.59 | |||
| Net income | ||||
| Net income | $32.77 | $33.39 | $16.55 | $45.8 |
| Income (for common shares) | $33.39 | $16.55 | $45.8 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $726.44 | $517.24 | $484.14 | $441.75 |
| Cost of revenue | $41.64 | $10.17 | $10.84 | $10.21 |
| Gross Profit | $684.8 | $507.07 | $473.3 | $431.54 |
| Operating activities | ||||
| Research & development | $351.62 | $361.57 | $239.41 | $319.13 |
| Selling, general & administrative | $406.56 | $369.09 | $396.03 | $388.66 |
| Total operating expenses | $758.18 | $730.66 | $643.74 | $718.13 |
| Operating income | -$73.38 | -$223.6 | -$170.44 | -$286.59 |
| Income from continuing operations | ||||
| EBIT | -$51.04 | -$213.44 | -$167.52 | -$280.97 |
| Income tax expense | $10.25 | $2.53 | $0.35 | $0.61 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$61.29 | -$215.97 | -$167.87 | -$281.58 |
| Income (for common shares) | -$61.29 | -$215.97 | -$167.87 | -$281.58 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $33.39 | $16.55 | $45.8 | |
| Operating activities | ||||
| Depreciation | $2.57 | $5.53 | $1.64 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $15.69 | $14.75 | $18.02 | |
| Total cash flows from operations | $25.01 | $29.08 | $85.39 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | -$56.19 | -$14.04 | -$0.35 | |
| Total cash flows from investing | -$152.69 | -$56.19 | -$14.04 | -$0.35 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.56 | $1.04 | $5.43 | |
| Net borrowings | ||||
| Total cash flows from financing | $4.88 | $3.56 | $1.04 | $5.43 |
| Effect of exchange rate | -$0.03 | $0 | $0.01 | -$0.01 |
| Change in cash and equivalents | -$30.51 | -$27.61 | $16.09 | $90.46 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$61.29 | -$215.97 | -$167.87 | -$281.58 |
| Operating activities | ||||
| Depreciation | $5.55 | $2.03 | $3.34 | $2.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $66.42 | $68.2 | $63.62 | $84.42 |
| Total cash flows from operations | $16.7 | -$114.03 | -$125.66 | -$136.17 |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$1.12 | -$7.59 | |
| Investments | $72.05 | $73.24 | -$69.98 | $200.1 |
| Total cash flows from investing | $32 | $73.24 | -$71.1 | $192.51 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $25.13 | $8.2 | $18.16 | $81 |
| Net borrowings | ||||
| Total cash flows from financing | $25.13 | $8.2 | $18.16 | $81 |
| Effect of exchange rate | -$0.02 | $0.01 | $0.01 | -$0.01 |
| Change in cash and equivalents | $73.81 | -$32.59 | -$178.59 | $137.33 |
News
Fundamentals
| Market cap | $2.69B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 166.35M |
| Revenue | $929.24M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $128.51M |
| Revenue Q/Q | 18.28% |
| Revenue Y/Y | 47.06% |
| P/E ratio | 20.95 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.90 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $0.77 |
|---|---|
| ROA | 14.71% |
| ROE | N/A |
| Debt/Equity | 0.73 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.29 |
| Quick ratio | 2.11 |